secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRIDEX CORP (IRIX)
CIK:        0001006045
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0000950170-25-046076
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iridex posts Q4 2024 revenue $12.7M, achieves positive adjusted EBITDA; net loss narrows to $0.8M
--------------------------------------------------------------------------------

- Q4 revenue $12.7M vs $12.5M YoY; adjusted EBITDA positive $0.4M vs ($2.0M) loss prior year.
- Net loss improved to $0.8M ($0.05/share) from $3.0M ($0.18/share); operating expenses down 24% to $6.1M.
- Cyclo G6 product family revenue $3.3M (+9% YoY); retina product revenue $7.3M (-3%).
- Cash $2.4M at year-end; subsequent $10M strategic investment from Novel Innovations at $2.00/share.
- Guidance: expects cash flow breakeven and positive adjusted EBITDA in 2025 on FY revenue consistent with 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006045/000095017025046076/0000950170-25-046076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006045/000095017025046076/irix-20250327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-046076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer